• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:宋光胜,宋文骞,李宏秋.《中国药典》2020年版(一部)中收载含罂粟壳成方制剂的汇总与分析[J].药学研究,2023,42(6):428-432[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2693次   下载 2738次 本文二维码信息
码上扫一扫!
《中国药典》2020年版(一部)中收载含罂粟壳成方制剂的汇总与分析
宋光胜1,宋文骞2,李宏秋3
字体:加大+|默认|缩小-
(1.山东省食品药品审评查验中心,山东 济南 250014;2.济南大学,山东 济南 250022;3.西安交通大学,陕西 西安 710100)
摘要:
目的 拓展含罂粟壳成方制剂的中医临床用药范围,规范含罂粟壳成方制剂使用说明与质量标准。方法 汇总《中国药典》2020年版(一部)(以下简称《中国药典》一部)中收载的含罂粟壳成方制剂,重点对含罂粟壳成方制剂的剂型、用法用量、使用禁忌、检验方法、处方中罂粟壳使用量、处方中罂粟壳的炮制方法等进行分析,提出了提高其临床安全用药水平的建议。结果 经对《中国药典》一部中收载的1 607个中药成方制剂处方项下的处方药味全部品种进行汇总统计分析,共有19个含有罂粟壳(含罂粟壳浸膏1个)的中药成方制剂,仅占《中国药典》(一部)全部中药成方制剂的1.24%。含罂粟壳成方制剂的基础研究比较薄弱,存在制剂品种少,个别品种用量不明确以及使用禁忌表述不规范等问题。结论 建议加强含罂粟壳成方制剂的基础研究,扩大临床用药范围,加强上市后安全性再评价,以达到规范使用,提高临床合理使用水平,保障含罂粟壳成方制剂的临床用药安全目的。
关键词:  《中国药典》  罂粟壳  成方制剂  质量标准  分析
DOI:10.13506/j.cnki.jpr.2023.06.015
基金项目:
Summary and analysis of prescription preparations containing poppy husk in the 2020 edition of Chinese Pharmacopoeia (Part I)
SONG Guangsheng1,SONG Wenqian2,LI Hongqiu3
(1.Shandong Center for Food and Drug Evaluation and Inspection, Jinan 250014,China;2.University of Jinan, Jinan 250022,China;3.Xi'an Jiaotong University, Xian 710100,China)
Abstract:
Objective To expand the scope of TCM clinical drug use of prescription preparations containing poppy husk, and standardize the instructions and quality standards for the use of prescription preparations containing poppy husk.Methods The formulations containing poppy husk collected in the 2020 edition of Chinese Pharmacopoeia (Part I) (hereinafter referred to as Part I) were summarized, focusing on the analysis of the dosage form, usage and dosage, usage taboo, inspection methods, the use of poppy husk in prescriptions and the processing methods of poppy husk in prescriptions, and suggestions were put forward to improve the level of clinical safe drug use. Results According to the summary statistics and analysis of all varieties of 1607 formulations of traditional Chinese medicine prescription collected in the first part of Chinese Pharmacopoeia, there were 19 formulations of traditional Chinese medicine prescription containing poppy husk (including 1 extract of poppy husk), accounting for only 1.24% of all formulations of traditional Chinese medicine prescription in the first part of Chinese Pharmacopoeia. The basic research of prescription preparation containing poppy husk is weak, and there are some problems, such as few varieties of preparation, unclear dosage of individual varieties and non-standard expression of taboo in use.Conclusion It is suggested to strengthen the basic research of prescription preparations containing poppy husk, expand the scope of clinical drug use, and strengthen post-marketing safety reevaluation, so as to achieve standardized use, improve the level of clinical rational use, and ensure the clinical drug safety of prescription preparations containing poppy husk.
Key words:  Chinese Pharmacopoeia  Poppy husk  Prescription preparation  Quality standard  Analysis  Discuss
今日访问量:2643    总访问量:55339157
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司